MX2020013306A - Uso de compuestos de halogeno para el tratamiento y prevencion de lesiones tisulares y sindrome post-cuidados intensivos. - Google Patents

Uso de compuestos de halogeno para el tratamiento y prevencion de lesiones tisulares y sindrome post-cuidados intensivos.

Info

Publication number
MX2020013306A
MX2020013306A MX2020013306A MX2020013306A MX2020013306A MX 2020013306 A MX2020013306 A MX 2020013306A MX 2020013306 A MX2020013306 A MX 2020013306A MX 2020013306 A MX2020013306 A MX 2020013306A MX 2020013306 A MX2020013306 A MX 2020013306A
Authority
MX
Mexico
Prior art keywords
intensive care
post
halogen compounds
prevention
treatment
Prior art date
Application number
MX2020013306A
Other languages
English (en)
Inventor
Mark B Roth
Michael L Morrison
Akiko Iwata
Stephen A Hill
John W Langston
Michael Andrew Insko
Original Assignee
Faraday Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faraday Pharmaceuticals Inc filed Critical Faraday Pharmaceuticals Inc
Publication of MX2020013306A publication Critical patent/MX2020013306A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invención se refiere al uso de compuestos de halógeno, incluido el yoduro, para tratar y prevenir el síndrome post-cuidados intensivos y el daño del tejido del músculo esquelético resultante de una lesión o enfermedad.
MX2020013306A 2018-06-08 2019-06-07 Uso de compuestos de halogeno para el tratamiento y prevencion de lesiones tisulares y sindrome post-cuidados intensivos. MX2020013306A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862682574P 2018-06-08 2018-06-08
US201862730927P 2018-09-13 2018-09-13
US201862730945P 2018-09-13 2018-09-13
PCT/US2019/036154 WO2019237065A1 (en) 2018-06-08 2019-06-07 Use of halogen compounds for the treatment and prevention of tissue injury and post-intensive care syndrome

Publications (1)

Publication Number Publication Date
MX2020013306A true MX2020013306A (es) 2021-05-12

Family

ID=68770655

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013306A MX2020013306A (es) 2018-06-08 2019-06-07 Uso de compuestos de halogeno para el tratamiento y prevencion de lesiones tisulares y sindrome post-cuidados intensivos.

Country Status (10)

Country Link
US (1) US20210252047A1 (es)
EP (1) EP3801565A4 (es)
JP (1) JP2021527130A (es)
KR (1) KR20210018898A (es)
CN (1) CN112469422A (es)
AU (1) AU2019282820A1 (es)
CA (1) CA3102792A1 (es)
IL (1) IL279221A (es)
MX (1) MX2020013306A (es)
WO (1) WO2019237065A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248335B1 (en) * 1997-10-29 2001-06-19 Symbollon Corporation Stabilized oral pharmaceutical composition containing iodide and iodate and method
CZ295765B6 (cs) * 1998-07-29 2005-10-12 Apa - Praha, S.R.O. Léčebný přípravek s virucidním účinkem
GB0525504D0 (en) * 2005-12-14 2006-01-25 Bristol Myers Squibb Co Antimicrobial composition
EP3104939B1 (en) * 2014-02-10 2024-05-01 Fred Hutchinson Cancer Center Treatment of heart attack and ischemic injury with sodium iodide

Also Published As

Publication number Publication date
EP3801565A4 (en) 2022-04-06
JP2021527130A (ja) 2021-10-11
IL279221A (en) 2021-01-31
WO2019237065A1 (en) 2019-12-12
CN112469422A (zh) 2021-03-09
EP3801565A1 (en) 2021-04-14
CA3102792A1 (en) 2019-12-12
KR20210018898A (ko) 2021-02-18
US20210252047A1 (en) 2021-08-19
AU2019282820A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
WO2018022664A8 (en) Neuromodulating compositions and related therapeutic methods for the treatment of inflammatory and autoimmune diseases
MX2019009443A (es) Metodos para tratar la influenza.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
IL285782A (en) Compounds, compositions, and methods for treating disease
IL276398A (en) Combined treatment for mastocytosis
NZ721500A (en) Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
MA39828A (fr) Usage médical
MX2019009753A (es) Composicion y metodos para prevenir lesion por radiacion y promover la regeneracion de tejidos.
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
IL273169A (en) A new combination of active substances for the treatment of advanced interstitial and lymphoid lung diseases
SG11202107325TA (en) Methods and compositions for the treatment of fabry disease
MX2017011937A (es) Antagonistas del receptor de nk-3 para el tratamiento terapeutico o cosmetico de la grasa corporal excesiva.
WO2016004413A3 (en) Gls1 inhibitors for treating disease
MX2022007285A (es) Compuestos, polimeros, dispositivos y usos de los mismos.
WO2019169333A8 (en) Afibrotic compounds, devices, and uses thereof
EA201691567A1 (ru) Способы лечения легких травм головного мозга
WO2016040169A3 (en) Mucolytic agents for use in tretaing pulmonary sarcoidosis
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
PH12020551179A1 (en) Methods for treating mitochondrial disorder
MX2020013100A (es) Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
MX2021001228A (es) Composicion para uso en la prevencion y/o tratamiento de la mucosa genitourinaria.
CR20210029A (es) MÉTODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA
MX2020013306A (es) Uso de compuestos de halogeno para el tratamiento y prevencion de lesiones tisulares y sindrome post-cuidados intensivos.